AstraZeneca is withdrawing its highly successful coronavirus vaccine, citing the availability of a plethora of new shots that has led to a decline in demand.
The vaccine — called Vaxzevria and developed in partnership with the University of Oxford — has been one of the main Covid-19 vaccines worldwide, with more than 3 billion doses supplied since the first was administered in the United Kingdom on January 4, 2021.
But the vaccine has not generated revenue for AstraZeneca since April 2023, the company said.
“As multiple, variant Covid-19 vaccines have … been developed, there is a surplus of available updated vaccines. This has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied,” it said in a statement shared with CNN Wednesday.
“AstraZeneca has therefore taken the decision to initiate withdrawal of the marketing authorizations for Vaxzevria within Europe,” it added.
In a notice on its website, the European Medicines Agency also announced the withdrawal, which means that Vaxzevria is no longer authorized to be marketed or sold in European Union countries.
Click this link for the original source of this article.
Author: Faith N
This content is courtesy of, and owned and copyrighted by, https://www.offthepress.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.